Market News & Analysis

Top Story

FTSE on a knife's edge

The FTSE is higher this morning, propped up by a strong rally in medical device maker Smith & Nephew but the news flowis  gradually eroding any investor optimism.

First the good news: Smith & Nephew jumped 8% after it reported sales that for the first time surpassed $5 bn. Lloyds Bank also rallied close to 4% despite reporting a 26% drop in annual profits as the decline was within the range that analysts had predicted.

But on a heavier note, the coronavirus provided much more to worry about. The outbreak has now spread into South Korea with the city of Daegu becoming Korea’s Wuhan. If the spread of the virus doesn’t reach its peak until April China’s growth could drop below 5% this year instead of the previously forecast 6%, which would then have repercussions on the growth of technology companies, phone makers, miners, oil producers, airlines and shippers.

This morning Air-France KLM and Maersk were the latest to join the chorus of firms warning about their revenue in the coming quarter because of COVID-19. China is trying to balance out some of the hit to the economy by cutting the lending rate, but it remains to be seen if the cuts are enough to stem the losses.

Brent crude stabilises

Brent crude prices are flat after an overnight rally but the commodity is now trading at its highest level since the outbreak of the virus in China.  The ongoing disruption in Libyan supplies and concerns that US sanctions could stifle the outflow of Venezuelan crude into the market are helping Brent crude trade close to $59.20.


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.